STAT February 19, 2024
Megan Molteni

Six years ago, the National Institutes of Health placed its biggest ever bet on precision medicine, launching a study to enroll over 1 million participants in an ambitious data-gathering gambit unmatched in its scope and diversity. Since then, Americans from all walks of life have been showing up and handing over their blood, spit, and pee to the project, dubbed “All of Us.” From those samples, scientists have recovered a trove of new genetic information — more than 275 million never-before-seen DNA variants.

The data, reported Monday in Nature, aim to address a longstanding lack of diversity in genomic datasets that has led to a narrow understanding of the biology of disease and undermined the promise of precision medicine.

Although...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine
BioAro Announces Real Time DNA Decoding Technology
23andMe: What If …
23andMe CEO Anne Wojcicki considers taking company private
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

Share This Article